Previous 10 | Next 10 |
Clinical-stage biotech Athersys (NASDAQ:ATHX) is trading lower in the morning hours Thursday after the company postponed its annual meeting of stockholders citing a need to add a proposal to implement a reverse stock split. Accordingly, the meeting initially set for next week will now be held...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Athersys ( ATHX ) stock tops our gainers today on clinical trial news. Symbotic (NASDAQ: SYM ) leads our losers after its market debut yesterday. Earnings and other data have more shares on the move this mo...
Annual Meeting of Stockholders rescheduled to Thursday, July 28, 2022, 8:30 a.m. ET Athersys, Inc. (Nasdaq: ATHX) today announced the postponement of its Annual Meeting of Stockholders, initially scheduled for Wednesday, June 15, 2022, at 8:30 a.m. ET. The Annual Meeting is ...
Webinar scheduled for June 14, 2022 at 5:00 p.m. ET Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today it will host a panel discussion with leading neurology expert...
Penny stocks are defined as shares of companies trading below $5. That may be the standard but it down not nearly explain the entire landscape of “cheap” stocks. Traders hunt for these lower-priced equities thanks to their inherent potential for quick gains. While Apple or Net...
FTSE Russell has released a preliminary lists of companies set to join or leave the Russell Microcap Index as part of its 2022 annual reconstitution. Notable health care additions include: Inovio Pharma (INO), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), Ocu...
At 2022 Russell indexes annual reconstitution, following notable health care stocks will be added to and deleted from the Russell 3000 Index. Notable additions: Clover Health Investments (CLOV), Aurinia Pharmaceuticals (AUPH), Nano-X Imaging (NNOX), ADMA Biologics (ADMA),&...
Athersys (NASDAQ:ATHX) will lay off 70% of its workforce by the end of June following results released in May that its MultiStem cell therapy candidate in ischemic stroke did not meet its primary endpoint. The company also said that COO William (B.J.) Lehmann left on May 3...
Workforce reduction up to 70% Conference call today at 5:00 p.m. ET Athersys, Inc. (Nasdaq: ATHX) today announced a corporate restructuring plan to reduce costs and prioritize its lead clinical programs. In connection with the restructuring, the Company is re...
The following slide deck was published by Athersys, Inc. in conjunction with this event. For further details see: Athersys (ATHX) Investor Presentation Treasure Data - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...